NSAIDs for analgesia in the era of COVID-19

Authors

Daniel L Herzberg, MedStar Georgetown University Hospital
Harry P Sukumaran, Wayne State University
Eugene R. Viscusi, Thomas Jefferson UniversityFollow

Document Type

Article

Publication Date

9-1-2020

Comments

This article is the author’s final published version in Regional Anesthesia and Pain Medicine, Volume 45, Issue 9, September 2020, Pages 677-678.

The published version is available at https://doi.org/10.1136/rapm-2020-101584. Copyright © American Society of Regional Anesthesia & Pain Medicine

Abstract

Globally, non-steroidal anti-inflammatory drugs (NSAIDs) are highly used to treat pain. With the rise of the COVID-19 pandemic, the safety of NSAIDs use has been called into question. These concerns are worthy of review. At present, there is no compelling data showing that NSAIDs worsen the severity of COVID-19 symptoms or increase one's likelihood of contracting the illness. For patients in pain and without symptoms that could potentially be attributed to COVID-19 (cough, fevers/chills, lethargy, myalgias, anosmia and so on), NSAIDs should continue to remain a viable option to provide analgesia to patients in need.

Recommended Citation

Herzberg, Daniel L; Sukumaran, Harry P; and Viscusi, Eugene R., "NSAIDs for analgesia in the era of COVID-19" (2020). Department of Anesthesiology Faculty Papers. Paper 64.
https://jdc.jefferson.edu/anfp/64

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License

PubMed ID

32499385

Language

English